Wellbeing Checkup: Biosimilars as Diffusers

In the oncology space, biologic drugs can be very expensive for patients. This can put added stress onto clinicians who may be wary about prescribing a biologic therapy to these patients without knowing whether the patient can afford the medication. Biosimilars, which high are clinically similar molecules that reference originator biologic medications and are offered at a lower price, offer a way to help patients, and practices, save money. Kathy Oubre, MS, delves into how financial toxicity brought on by the inability to afford expensive biologics impacts both patients and providers and hones in on how biosimilars offer a way around those concerns.